Hepatitis A Vaccine Brand Names
The brand names of hepatitis A vaccines available in the United States are Havrix, Vaqta, and Twinrix (a combination hepatitis A and B vaccine). 1
Single-Antigen Hepatitis A Vaccines
Havrix
- Manufactured by GlaxoSmithKline (Rixensart, Belgium) 1
- Contains inactivated hepatitis A virus grown in human diploid fibroblast cells 1
- Contains 2-phenoxyethanol as a preservative 1
- Available in two formulations:
- Administered as a 2-dose schedule 1
Vaqta
- Manufactured by Merck & Co., Inc. (Whitehouse Station, New Jersey) 1
- Contains inactivated hepatitis A virus grown in human diploid fibroblast cells 1
- Formulated without a preservative 1
- Available in two formulations:
- Administered as a 2-dose schedule 1
Combination Hepatitis A and B Vaccine
Twinrix
- Manufactured by GlaxoSmithKline 1
- Contains both hepatitis A and hepatitis B antigens 1
- Licensed for use in persons aged ≥18 years only 1
- Contains 720 ELU of hepatitis A antigen (half of the Havrix adult dose) and 20 μg of recombinant hepatitis B surface antigen 1
- Contains 2-phenoxyethanol as a preservative 1
- Administered as a 3-dose series on a 0-, 1-, and 6-month schedule 1
- FDA approved in May 2001 2
Vaccine Characteristics
- All hepatitis A vaccines licensed in the US are inactivated, whole-cell virus vaccines 1
- All are administered intramuscularly into the deltoid muscle 1
- None of the hepatitis A vaccines licensed in the United States have ever contained thimerosal 1
- All contain aluminum hydroxide as an adjuvant 1
Immunogenicity and Effectiveness
- Within 1 month of receiving a first dose of hepatitis A vaccine, 97% of children and adolescents and 95% of adults develop protective antibody levels 1
- After completing the recommended schedule, virtually 100% of individuals are protected against hepatitis A infection 1
- For Twinrix, antibody responses to both hepatitis A and B antigens are equivalent to responses seen after the single-antigen vaccines are administered separately 1, 3
- Long-term studies show antibody persistence for at least 10 years after primary vaccination with Twinrix 4